nodes	percent_of_prediction	percent_of_DWPC	metapath
Asenapine—CYP1A2—Progesterone—uterine cancer	0.0638	0.236	CbGbCtD
Asenapine—CYP2D6—Progesterone—uterine cancer	0.0526	0.195	CbGbCtD
Asenapine—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0505	0.187	CbGbCtD
Asenapine—CYP3A4—Progesterone—uterine cancer	0.0334	0.124	CbGbCtD
Asenapine—CYP1A2—Etoposide—uterine cancer	0.0286	0.106	CbGbCtD
Asenapine—CYP2D6—Doxorubicin—uterine cancer	0.016	0.0594	CbGbCtD
Asenapine—CYP3A4—Etoposide—uterine cancer	0.015	0.0554	CbGbCtD
Asenapine—CYP3A4—Doxorubicin—uterine cancer	0.0102	0.0378	CbGbCtD
Asenapine—HTR1E—myometrium—uterine cancer	0.00758	0.0522	CbGeAlD
Asenapine—HTR1B—artery—uterine cancer	0.00742	0.0511	CbGeAlD
Asenapine—HTR1D—artery—uterine cancer	0.00718	0.0495	CbGeAlD
Asenapine—UGT1A4—renal system—uterine cancer	0.00631	0.0435	CbGeAlD
Asenapine—HTR7—artery—uterine cancer	0.00572	0.0394	CbGeAlD
Asenapine—HTR1E—female gonad—uterine cancer	0.00402	0.0277	CbGeAlD
Asenapine—HTR2A—artery—uterine cancer	0.00357	0.0246	CbGeAlD
Asenapine—HTR2B—myometrium—uterine cancer	0.00323	0.0222	CbGeAlD
Asenapine—ADRA2C—myometrium—uterine cancer	0.00254	0.0175	CbGeAlD
Asenapine—HTR2B—uterine cervix—uterine cancer	0.00251	0.0173	CbGeAlD
Asenapine—HTR2B—smooth muscle tissue—uterine cancer	0.00244	0.0168	CbGeAlD
Asenapine—HTR2B—decidua—uterine cancer	0.00239	0.0165	CbGeAlD
Asenapine—HTR2B—endometrium—uterine cancer	0.00227	0.0156	CbGeAlD
Asenapine—HTR7—epithelium—uterine cancer	0.00217	0.0149	CbGeAlD
Asenapine—HTR1A—renal system—uterine cancer	0.00211	0.0145	CbGeAlD
Asenapine—HTR2B—uterus—uterine cancer	0.00209	0.0144	CbGeAlD
Asenapine—ADRA1A—epithelium—uterine cancer	0.00209	0.0144	CbGeAlD
Asenapine—HTR7—smooth muscle tissue—uterine cancer	0.00209	0.0144	CbGeAlD
Asenapine—HTR1B—female reproductive system—uterine cancer	0.00209	0.0144	CbGeAlD
Asenapine—HRH1—myometrium—uterine cancer	0.00206	0.0142	CbGeAlD
Asenapine—ADRA2A—myometrium—uterine cancer	0.00203	0.014	CbGeAlD
Asenapine—HTR1D—female reproductive system—uterine cancer	0.00202	0.0139	CbGeAlD
Asenapine—HTR7—renal system—uterine cancer	0.00201	0.0139	CbGeAlD
Asenapine—HTR2C—female reproductive system—uterine cancer	0.002	0.0138	CbGeAlD
Asenapine—ADRA2C—uterine cervix—uterine cancer	0.00198	0.0136	CbGeAlD
Asenapine—ADRB1—female reproductive system—uterine cancer	0.00197	0.0135	CbGeAlD
Asenapine—ADRA1A—renal system—uterine cancer	0.00194	0.0134	CbGeAlD
Asenapine—SLC6A4—female reproductive system—uterine cancer	0.0019	0.0131	CbGeAlD
Asenapine—ADRA2C—decidua—uterine cancer	0.00188	0.013	CbGeAlD
Asenapine—HTR2B—female reproductive system—uterine cancer	0.00188	0.013	CbGeAlD
Asenapine—HRH2—lymph node—uterine cancer	0.00185	0.0128	CbGeAlD
Asenapine—ADRA2C—renal system—uterine cancer	0.00185	0.0127	CbGeAlD
Asenapine—ADRA2C—endometrium—uterine cancer	0.00179	0.0123	CbGeAlD
Asenapine—ADRA2C—mammalian vulva—uterine cancer	0.00173	0.0119	CbGeAlD
Asenapine—HTR2B—vagina—uterine cancer	0.0017	0.0117	CbGeAlD
Asenapine—Arthralgia—Progesterone—uterine cancer	0.00168	0.00313	CcSEcCtD
Asenapine—Tremor—Medroxyprogesterone Acetate—uterine cancer	0.00168	0.00312	CcSEcCtD
Asenapine—Anxiety—Progesterone—uterine cancer	0.00168	0.00312	CcSEcCtD
Asenapine—Agranulocytosis—Dactinomycin—uterine cancer	0.00167	0.0031	CcSEcCtD
Asenapine—Blister—Doxorubicin—uterine cancer	0.00166	0.00309	CcSEcCtD
Asenapine—Anaemia—Medroxyprogesterone Acetate—uterine cancer	0.00165	0.00308	CcSEcCtD
Asenapine—ADRA2C—uterus—uterine cancer	0.00165	0.0113	CbGeAlD
Asenapine—Agitation—Medroxyprogesterone Acetate—uterine cancer	0.00164	0.00306	CcSEcCtD
Asenapine—Dry mouth—Progesterone—uterine cancer	0.00164	0.00306	CcSEcCtD
Asenapine—Angioedema—Medroxyprogesterone Acetate—uterine cancer	0.00163	0.00304	CcSEcCtD
Asenapine—HRH1—epithelium—uterine cancer	0.00162	0.0112	CbGeAlD
Asenapine—Malaise—Medroxyprogesterone Acetate—uterine cancer	0.00161	0.003	CcSEcCtD
Asenapine—HTR7—female reproductive system—uterine cancer	0.00161	0.0111	CbGeAlD
Asenapine—Anaphylactic shock—Progesterone—uterine cancer	0.00161	0.003	CcSEcCtD
Asenapine—HRH1—uterine cervix—uterine cancer	0.00161	0.0111	CbGeAlD
Asenapine—CYP1A2—renal system—uterine cancer	0.00161	0.0111	CbGeAlD
Asenapine—Syncope—Medroxyprogesterone Acetate—uterine cancer	0.0016	0.00299	CcSEcCtD
Asenapine—Shock—Progesterone—uterine cancer	0.00159	0.00295	CcSEcCtD
Asenapine—Nervous system disorder—Progesterone—uterine cancer	0.00158	0.00294	CcSEcCtD
Asenapine—ADRA2A—uterine cervix—uterine cancer	0.00158	0.0109	CbGeAlD
Asenapine—Tachycardia—Progesterone—uterine cancer	0.00157	0.00293	CcSEcCtD
Asenapine—Loss of consciousness—Medroxyprogesterone Acetate—uterine cancer	0.00157	0.00293	CcSEcCtD
Asenapine—HRH1—smooth muscle tissue—uterine cancer	0.00156	0.0107	CbGeAlD
Asenapine—Blood disorder—Epirubicin—uterine cancer	0.00155	0.00289	CcSEcCtD
Asenapine—Convulsion—Medroxyprogesterone Acetate—uterine cancer	0.00155	0.00289	CcSEcCtD
Asenapine—Liver injury—Epirubicin—uterine cancer	0.00154	0.00286	CcSEcCtD
Asenapine—HRH1—decidua—uterine cancer	0.00153	0.0105	CbGeAlD
Asenapine—Arthralgia—Medroxyprogesterone Acetate—uterine cancer	0.00152	0.00284	CcSEcCtD
Asenapine—Anxiety—Medroxyprogesterone Acetate—uterine cancer	0.00152	0.00283	CcSEcCtD
Asenapine—Hypotension—Progesterone—uterine cancer	0.00151	0.0028	CcSEcCtD
Asenapine—ADRA2A—decidua—uterine cancer	0.0015	0.0103	CbGeAlD
Asenapine—Dry mouth—Medroxyprogesterone Acetate—uterine cancer	0.00149	0.00277	CcSEcCtD
Asenapine—Alanine aminotransferase increased—Etoposide—uterine cancer	0.00148	0.00275	CcSEcCtD
Asenapine—Amenorrhoea—Epirubicin—uterine cancer	0.00147	0.00274	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Progesterone—uterine cancer	0.00147	0.00273	CcSEcCtD
Asenapine—Anaphylactic shock—Medroxyprogesterone Acetate—uterine cancer	0.00146	0.00272	CcSEcCtD
Asenapine—Insomnia—Progesterone—uterine cancer	0.00146	0.00271	CcSEcCtD
Asenapine—HRH1—endometrium—uterine cancer	0.00145	0.01	CbGeAlD
Asenapine—Dysphagia—Etoposide—uterine cancer	0.00145	0.0027	CcSEcCtD
Asenapine—Dyspnoea—Progesterone—uterine cancer	0.00144	0.00267	CcSEcCtD
Asenapine—Shock—Medroxyprogesterone Acetate—uterine cancer	0.00144	0.00267	CcSEcCtD
Asenapine—Blood disorder—Doxorubicin—uterine cancer	0.00143	0.00267	CcSEcCtD
Asenapine—Somnolence—Progesterone—uterine cancer	0.00143	0.00267	CcSEcCtD
Asenapine—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.00143	0.00267	CcSEcCtD
Asenapine—Thrombocytopenia—Medroxyprogesterone Acetate—uterine cancer	0.00143	0.00266	CcSEcCtD
Asenapine—ADRA2A—endometrium—uterine cancer	0.00143	0.00982	CbGeAlD
Asenapine—Tachycardia—Medroxyprogesterone Acetate—uterine cancer	0.00143	0.00265	CcSEcCtD
Asenapine—Liver injury—Doxorubicin—uterine cancer	0.00142	0.00265	CcSEcCtD
Asenapine—Dyspepsia—Progesterone—uterine cancer	0.00142	0.00264	CcSEcCtD
Asenapine—HRH1—mammalian vulva—uterine cancer	0.00141	0.00967	CbGeAlD
Asenapine—Gastrointestinal disorder—Progesterone—uterine cancer	0.00139	0.00259	CcSEcCtD
Asenapine—Fatigue—Progesterone—uterine cancer	0.00139	0.00259	CcSEcCtD
Asenapine—ADRA2A—mammalian vulva—uterine cancer	0.00138	0.0095	CbGeAlD
Asenapine—Dyskinesia—Epirubicin—uterine cancer	0.00138	0.00256	CcSEcCtD
Asenapine—Constipation—Progesterone—uterine cancer	0.00138	0.00256	CcSEcCtD
Asenapine—Ulcer—Epirubicin—uterine cancer	0.00137	0.00255	CcSEcCtD
Asenapine—Dysarthria—Epirubicin—uterine cancer	0.00137	0.00255	CcSEcCtD
Asenapine—Hypotension—Medroxyprogesterone Acetate—uterine cancer	0.00136	0.00254	CcSEcCtD
Asenapine—Amenorrhoea—Doxorubicin—uterine cancer	0.00136	0.00254	CcSEcCtD
Asenapine—Neutropenia—Etoposide—uterine cancer	0.00136	0.00252	CcSEcCtD
Asenapine—HTR2A—epithelium—uterine cancer	0.00135	0.00932	CbGeAlD
Asenapine—ADRA2C—female gonad—uterine cancer	0.00135	0.00928	CbGeAlD
Asenapine—ADRA2C—vagina—uterine cancer	0.00134	0.00922	CbGeAlD
Asenapine—Inflammation—Epirubicin—uterine cancer	0.00134	0.00249	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.00133	0.00248	CcSEcCtD
Asenapine—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.00132	0.00246	CcSEcCtD
Asenapine—ADRA2A—uterus—uterine cancer	0.00131	0.00905	CbGeAlD
Asenapine—HTR2A—smooth muscle tissue—uterine cancer	0.0013	0.00898	CbGeAlD
Asenapine—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.0013	0.00242	CcSEcCtD
Asenapine—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.0013	0.00242	CcSEcCtD
Asenapine—Pulmonary embolism—Epirubicin—uterine cancer	0.0013	0.00241	CcSEcCtD
Asenapine—Anaemia—Dactinomycin—uterine cancer	0.00129	0.0024	CcSEcCtD
Asenapine—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.00129	0.00239	CcSEcCtD
Asenapine—Dyskinesia—Doxorubicin—uterine cancer	0.00128	0.00237	CcSEcCtD
Asenapine—Ulcer—Doxorubicin—uterine cancer	0.00127	0.00236	CcSEcCtD
Asenapine—Dysarthria—Doxorubicin—uterine cancer	0.00127	0.00236	CcSEcCtD
Asenapine—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00126	0.00235	CcSEcCtD
Asenapine—Stomatitis—Etoposide—uterine cancer	0.00126	0.00234	CcSEcCtD
Asenapine—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.00126	0.00234	CcSEcCtD
Asenapine—Malaise—Dactinomycin—uterine cancer	0.00126	0.00234	CcSEcCtD
Asenapine—Salivary hypersecretion—Epirubicin—uterine cancer	0.00126	0.00234	CcSEcCtD
Asenapine—HTR2A—renal system—uterine cancer	0.00125	0.00864	CbGeAlD
Asenapine—Leukopenia—Dactinomycin—uterine cancer	0.00125	0.00233	CcSEcCtD
Asenapine—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.00125	0.00232	CcSEcCtD
Asenapine—Skin exfoliation—Epirubicin—uterine cancer	0.00124	0.0023	CcSEcCtD
Asenapine—Inflammation—Doxorubicin—uterine cancer	0.00124	0.0023	CcSEcCtD
Asenapine—Hepatobiliary disease—Etoposide—uterine cancer	0.00122	0.00228	CcSEcCtD
Asenapine—Agranulocytosis—Etoposide—uterine cancer	0.00121	0.00224	CcSEcCtD
Asenapine—HRH1—female reproductive system—uterine cancer	0.0012	0.00829	CbGeAlD
Asenapine—Pulmonary embolism—Doxorubicin—uterine cancer	0.0012	0.00223	CcSEcCtD
Asenapine—Hypersensitivity—Progesterone—uterine cancer	0.00119	0.00221	CcSEcCtD
Asenapine—ADRA2A—female reproductive system—uterine cancer	0.00118	0.00814	CbGeAlD
Asenapine—Mouth ulceration—Epirubicin—uterine cancer	0.00117	0.00218	CcSEcCtD
Asenapine—Salivary hypersecretion—Doxorubicin—uterine cancer	0.00116	0.00217	CcSEcCtD
Asenapine—CYP3A4—renal system—uterine cancer	0.00116	0.008	CbGeAlD
Asenapine—Asthenia—Progesterone—uterine cancer	0.00116	0.00215	CcSEcCtD
Asenapine—Skin exfoliation—Doxorubicin—uterine cancer	0.00114	0.00213	CcSEcCtD
Asenapine—CYP2D6—renal system—uterine cancer	0.00114	0.00787	CbGeAlD
Asenapine—Thrombocytopenia—Dactinomycin—uterine cancer	0.00112	0.00208	CcSEcCtD
Asenapine—HTR2B—lymph node—uterine cancer	0.0011	0.00758	CbGeAlD
Asenapine—HRH1—female gonad—uterine cancer	0.00109	0.00754	CbGeAlD
Asenapine—HRH1—vagina—uterine cancer	0.00109	0.00749	CbGeAlD
Asenapine—Eye disorder—Etoposide—uterine cancer	0.00108	0.00202	CcSEcCtD
Asenapine—Mouth ulceration—Doxorubicin—uterine cancer	0.00108	0.00202	CcSEcCtD
Asenapine—Diabetes mellitus—Epirubicin—uterine cancer	0.00108	0.00201	CcSEcCtD
Asenapine—Cardiac disorder—Etoposide—uterine cancer	0.00108	0.002	CcSEcCtD
Asenapine—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.00108	0.002	CcSEcCtD
Asenapine—ADRA2A—female gonad—uterine cancer	0.00108	0.00741	CbGeAlD
Asenapine—ADRA2A—vagina—uterine cancer	0.00107	0.00736	CbGeAlD
Asenapine—Dizziness—Progesterone—uterine cancer	0.00107	0.00198	CcSEcCtD
Asenapine—Angiopathy—Etoposide—uterine cancer	0.00105	0.00196	CcSEcCtD
Asenapine—Immune system disorder—Etoposide—uterine cancer	0.00105	0.00195	CcSEcCtD
Asenapine—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.00105	0.00195	CcSEcCtD
Asenapine—Mediastinal disorder—Etoposide—uterine cancer	0.00105	0.00195	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.00104	0.00193	CcSEcCtD
Asenapine—Vomiting—Progesterone—uterine cancer	0.00102	0.00191	CcSEcCtD
Asenapine—Rash—Progesterone—uterine cancer	0.00102	0.00189	CcSEcCtD
Asenapine—Dermatitis—Progesterone—uterine cancer	0.00102	0.00189	CcSEcCtD
Asenapine—Headache—Progesterone—uterine cancer	0.00101	0.00188	CcSEcCtD
Asenapine—HTR2A—female reproductive system—uterine cancer	0.00101	0.00692	CbGeAlD
Asenapine—Increased appetite—Epirubicin—uterine cancer	0.001	0.00186	CcSEcCtD
Asenapine—Diabetes mellitus—Doxorubicin—uterine cancer	0.001	0.00186	CcSEcCtD
Asenapine—Dysgeusia—Etoposide—uterine cancer	0.000989	0.00184	CcSEcCtD
Asenapine—Dermatitis bullous—Epirubicin—uterine cancer	0.000984	0.00183	CcSEcCtD
Asenapine—Fatigue—Dactinomycin—uterine cancer	0.000982	0.00183	CcSEcCtD
Asenapine—Anaphylactoid reaction—Epirubicin—uterine cancer	0.000971	0.00181	CcSEcCtD
Asenapine—Muscle spasms—Etoposide—uterine cancer	0.000971	0.00181	CcSEcCtD
Asenapine—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000966	0.0018	CcSEcCtD
Asenapine—Nausea—Progesterone—uterine cancer	0.000957	0.00178	CcSEcCtD
Asenapine—Hyponatraemia—Epirubicin—uterine cancer	0.000944	0.00176	CcSEcCtD
Asenapine—Pain in extremity—Epirubicin—uterine cancer	0.00094	0.00175	CcSEcCtD
Asenapine—Osteoarthritis—Epirubicin—uterine cancer	0.00094	0.00175	CcSEcCtD
Asenapine—Anaemia—Etoposide—uterine cancer	0.000934	0.00174	CcSEcCtD
Asenapine—CYP3A4—female reproductive system—uterine cancer	0.00093	0.00641	CbGeAlD
Asenapine—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000929	0.00173	CcSEcCtD
Asenapine—Increased appetite—Doxorubicin—uterine cancer	0.000926	0.00172	CcSEcCtD
Asenapine—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000921	0.00171	CcSEcCtD
Asenapine—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.00092	0.00171	CcSEcCtD
Asenapine—CYP2D6—female reproductive system—uterine cancer	0.000916	0.0063	CbGeAlD
Asenapine—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000915	0.0017	CcSEcCtD
Asenapine—Malaise—Etoposide—uterine cancer	0.000911	0.0017	CcSEcCtD
Asenapine—Dermatitis bullous—Doxorubicin—uterine cancer	0.00091	0.00169	CcSEcCtD
Asenapine—HTR2A—vagina—uterine cancer	0.000909	0.00626	CbGeAlD
Asenapine—Leukopenia—Etoposide—uterine cancer	0.000904	0.00168	CcSEcCtD
Asenapine—Anaphylactoid reaction—Doxorubicin—uterine cancer	0.000899	0.00167	CcSEcCtD
Asenapine—Loss of consciousness—Etoposide—uterine cancer	0.000888	0.00165	CcSEcCtD
Asenapine—Convulsion—Etoposide—uterine cancer	0.000875	0.00163	CcSEcCtD
Asenapine—Hyponatraemia—Doxorubicin—uterine cancer	0.000873	0.00163	CcSEcCtD
Asenapine—Hypertension—Etoposide—uterine cancer	0.000872	0.00162	CcSEcCtD
Asenapine—Osteoarthritis—Doxorubicin—uterine cancer	0.00087	0.00162	CcSEcCtD
Asenapine—Pain in extremity—Doxorubicin—uterine cancer	0.00087	0.00162	CcSEcCtD
Asenapine—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000867	0.00161	CcSEcCtD
Asenapine—ADRA2C—lymph node—uterine cancer	0.000867	0.00597	CbGeAlD
Asenapine—Orthostatic hypotension—Epirubicin—uterine cancer	0.000859	0.0016	CcSEcCtD
Asenapine—Breast disorder—Epirubicin—uterine cancer	0.00085	0.00158	CcSEcCtD
Asenapine—Hypersensitivity—Dactinomycin—uterine cancer	0.000839	0.00156	CcSEcCtD
Asenapine—CYP2D6—female gonad—uterine cancer	0.000833	0.00574	CbGeAlD
Asenapine—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000829	0.00154	CcSEcCtD
Asenapine—Anaphylactic shock—Etoposide—uterine cancer	0.000824	0.00153	CcSEcCtD
Asenapine—Asthenia—Dactinomycin—uterine cancer	0.000817	0.00152	CcSEcCtD
Asenapine—Dysphagia—Epirubicin—uterine cancer	0.000813	0.00151	CcSEcCtD
Asenapine—Thrombocytopenia—Etoposide—uterine cancer	0.000807	0.0015	CcSEcCtD
Asenapine—Tachycardia—Etoposide—uterine cancer	0.000805	0.0015	CcSEcCtD
Asenapine—Orthostatic hypotension—Doxorubicin—uterine cancer	0.000795	0.00148	CcSEcCtD
Asenapine—Breast disorder—Doxorubicin—uterine cancer	0.000786	0.00146	CcSEcCtD
Asenapine—Hypotension—Etoposide—uterine cancer	0.00077	0.00143	CcSEcCtD
Asenapine—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000767	0.00143	CcSEcCtD
Asenapine—Neutropenia—Epirubicin—uterine cancer	0.00076	0.00141	CcSEcCtD
Asenapine—Dysphagia—Doxorubicin—uterine cancer	0.000752	0.0014	CcSEcCtD
Asenapine—Weight increased—Epirubicin—uterine cancer	0.00074	0.00138	CcSEcCtD
Asenapine—Dyspnoea—Etoposide—uterine cancer	0.000735	0.00137	CcSEcCtD
Asenapine—Hyperglycaemia—Epirubicin—uterine cancer	0.000733	0.00136	CcSEcCtD
Asenapine—Somnolence—Etoposide—uterine cancer	0.000733	0.00136	CcSEcCtD
Asenapine—Vomiting—Dactinomycin—uterine cancer	0.000724	0.00135	CcSEcCtD
Asenapine—Rash—Dactinomycin—uterine cancer	0.000718	0.00134	CcSEcCtD
Asenapine—Gastrointestinal disorder—Etoposide—uterine cancer	0.000712	0.00132	CcSEcCtD
Asenapine—Fatigue—Etoposide—uterine cancer	0.000711	0.00132	CcSEcCtD
Asenapine—Stomatitis—Epirubicin—uterine cancer	0.000706	0.00131	CcSEcCtD
Asenapine—Constipation—Etoposide—uterine cancer	0.000705	0.00131	CcSEcCtD
Asenapine—HRH1—lymph node—uterine cancer	0.000704	0.00485	CbGeAlD
Asenapine—Neutropenia—Doxorubicin—uterine cancer	0.000703	0.00131	CcSEcCtD
Asenapine—ADRA2A—lymph node—uterine cancer	0.000691	0.00476	CbGeAlD
Asenapine—Hepatobiliary disease—Epirubicin—uterine cancer	0.000685	0.00128	CcSEcCtD
Asenapine—Weight increased—Doxorubicin—uterine cancer	0.000684	0.00127	CcSEcCtD
Asenapine—Hyperglycaemia—Doxorubicin—uterine cancer	0.000678	0.00126	CcSEcCtD
Asenapine—Nausea—Dactinomycin—uterine cancer	0.000677	0.00126	CcSEcCtD
Asenapine—Agranulocytosis—Epirubicin—uterine cancer	0.000676	0.00126	CcSEcCtD
Asenapine—Stomatitis—Doxorubicin—uterine cancer	0.000653	0.00122	CcSEcCtD
Asenapine—Oedema peripheral—Epirubicin—uterine cancer	0.000641	0.00119	CcSEcCtD
Asenapine—Connective tissue disorder—Epirubicin—uterine cancer	0.000639	0.00119	CcSEcCtD
Asenapine—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000634	0.00118	CcSEcCtD
Asenapine—Agranulocytosis—Doxorubicin—uterine cancer	0.000626	0.00116	CcSEcCtD
Asenapine—Eye disorder—Epirubicin—uterine cancer	0.000608	0.00113	CcSEcCtD
Asenapine—Hypersensitivity—Etoposide—uterine cancer	0.000607	0.00113	CcSEcCtD
Asenapine—Cardiac disorder—Epirubicin—uterine cancer	0.000604	0.00112	CcSEcCtD
Asenapine—Oedema peripheral—Doxorubicin—uterine cancer	0.000593	0.0011	CcSEcCtD
Asenapine—Asthenia—Etoposide—uterine cancer	0.000591	0.0011	CcSEcCtD
Asenapine—Connective tissue disorder—Doxorubicin—uterine cancer	0.000591	0.0011	CcSEcCtD
Asenapine—Angiopathy—Epirubicin—uterine cancer	0.00059	0.0011	CcSEcCtD
Asenapine—Immune system disorder—Epirubicin—uterine cancer	0.000588	0.00109	CcSEcCtD
Asenapine—Mediastinal disorder—Epirubicin—uterine cancer	0.000586	0.00109	CcSEcCtD
Asenapine—Mental disorder—Epirubicin—uterine cancer	0.00057	0.00106	CcSEcCtD
Asenapine—Malnutrition—Epirubicin—uterine cancer	0.000566	0.00105	CcSEcCtD
Asenapine—Eye disorder—Doxorubicin—uterine cancer	0.000562	0.00105	CcSEcCtD
Asenapine—Cardiac disorder—Doxorubicin—uterine cancer	0.000559	0.00104	CcSEcCtD
Asenapine—Dysgeusia—Epirubicin—uterine cancer	0.000554	0.00103	CcSEcCtD
Asenapine—Angiopathy—Doxorubicin—uterine cancer	0.000546	0.00102	CcSEcCtD
Asenapine—Dizziness—Etoposide—uterine cancer	0.000545	0.00101	CcSEcCtD
Asenapine—Muscle spasms—Epirubicin—uterine cancer	0.000544	0.00101	CcSEcCtD
Asenapine—Immune system disorder—Doxorubicin—uterine cancer	0.000544	0.00101	CcSEcCtD
Asenapine—Mediastinal disorder—Doxorubicin—uterine cancer	0.000542	0.00101	CcSEcCtD
Asenapine—Mental disorder—Doxorubicin—uterine cancer	0.000527	0.000981	CcSEcCtD
Asenapine—Vomiting—Etoposide—uterine cancer	0.000524	0.000976	CcSEcCtD
Asenapine—Malnutrition—Doxorubicin—uterine cancer	0.000524	0.000975	CcSEcCtD
Asenapine—Anaemia—Epirubicin—uterine cancer	0.000523	0.000974	CcSEcCtD
Asenapine—Agitation—Epirubicin—uterine cancer	0.00052	0.000968	CcSEcCtD
Asenapine—Rash—Etoposide—uterine cancer	0.00052	0.000967	CcSEcCtD
Asenapine—Dermatitis—Etoposide—uterine cancer	0.000519	0.000966	CcSEcCtD
Asenapine—Headache—Etoposide—uterine cancer	0.000516	0.000961	CcSEcCtD
Asenapine—Dysgeusia—Doxorubicin—uterine cancer	0.000513	0.000955	CcSEcCtD
Asenapine—Malaise—Epirubicin—uterine cancer	0.000511	0.00095	CcSEcCtD
Asenapine—Syncope—Epirubicin—uterine cancer	0.000508	0.000945	CcSEcCtD
Asenapine—Leukopenia—Epirubicin—uterine cancer	0.000507	0.000943	CcSEcCtD
Asenapine—Muscle spasms—Doxorubicin—uterine cancer	0.000504	0.000937	CcSEcCtD
Asenapine—Loss of consciousness—Epirubicin—uterine cancer	0.000498	0.000926	CcSEcCtD
Asenapine—Convulsion—Epirubicin—uterine cancer	0.000491	0.000913	CcSEcCtD
Asenapine—Nausea—Etoposide—uterine cancer	0.00049	0.000911	CcSEcCtD
Asenapine—Hypertension—Epirubicin—uterine cancer	0.000489	0.00091	CcSEcCtD
Asenapine—Anaemia—Doxorubicin—uterine cancer	0.000484	0.000901	CcSEcCtD
Asenapine—Arthralgia—Epirubicin—uterine cancer	0.000482	0.000897	CcSEcCtD
Asenapine—Agitation—Doxorubicin—uterine cancer	0.000481	0.000896	CcSEcCtD
Asenapine—Anxiety—Epirubicin—uterine cancer	0.00048	0.000894	CcSEcCtD
Asenapine—Malaise—Doxorubicin—uterine cancer	0.000472	0.000879	CcSEcCtD
Asenapine—Dry mouth—Epirubicin—uterine cancer	0.000471	0.000877	CcSEcCtD
Asenapine—Syncope—Doxorubicin—uterine cancer	0.00047	0.000874	CcSEcCtD
Asenapine—Leukopenia—Doxorubicin—uterine cancer	0.000469	0.000873	CcSEcCtD
Asenapine—Anaphylactic shock—Epirubicin—uterine cancer	0.000462	0.00086	CcSEcCtD
Asenapine—Loss of consciousness—Doxorubicin—uterine cancer	0.00046	0.000857	CcSEcCtD
Asenapine—Shock—Epirubicin—uterine cancer	0.000455	0.000846	CcSEcCtD
Asenapine—Convulsion—Doxorubicin—uterine cancer	0.000454	0.000845	CcSEcCtD
Asenapine—Nervous system disorder—Epirubicin—uterine cancer	0.000453	0.000843	CcSEcCtD
Asenapine—Thrombocytopenia—Epirubicin—uterine cancer	0.000452	0.000842	CcSEcCtD
Asenapine—Hypertension—Doxorubicin—uterine cancer	0.000452	0.000842	CcSEcCtD
Asenapine—Tachycardia—Epirubicin—uterine cancer	0.000451	0.000839	CcSEcCtD
Asenapine—Arthralgia—Doxorubicin—uterine cancer	0.000446	0.00083	CcSEcCtD
Asenapine—Anxiety—Doxorubicin—uterine cancer	0.000444	0.000827	CcSEcCtD
Asenapine—Dry mouth—Doxorubicin—uterine cancer	0.000436	0.000812	CcSEcCtD
Asenapine—Hypotension—Epirubicin—uterine cancer	0.000432	0.000804	CcSEcCtD
Asenapine—Anaphylactic shock—Doxorubicin—uterine cancer	0.000428	0.000796	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000421	0.000784	CcSEcCtD
Asenapine—Shock—Doxorubicin—uterine cancer	0.000421	0.000783	CcSEcCtD
Asenapine—Nervous system disorder—Doxorubicin—uterine cancer	0.000419	0.00078	CcSEcCtD
Asenapine—Thrombocytopenia—Doxorubicin—uterine cancer	0.000419	0.000779	CcSEcCtD
Asenapine—Insomnia—Epirubicin—uterine cancer	0.000418	0.000778	CcSEcCtD
Asenapine—Tachycardia—Doxorubicin—uterine cancer	0.000417	0.000777	CcSEcCtD
Asenapine—Dyspnoea—Epirubicin—uterine cancer	0.000412	0.000767	CcSEcCtD
Asenapine—Somnolence—Epirubicin—uterine cancer	0.000411	0.000765	CcSEcCtD
Asenapine—Dyspepsia—Epirubicin—uterine cancer	0.000407	0.000757	CcSEcCtD
Asenapine—Hypotension—Doxorubicin—uterine cancer	0.0004	0.000744	CcSEcCtD
Asenapine—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000399	0.000742	CcSEcCtD
Asenapine—Fatigue—Epirubicin—uterine cancer	0.000398	0.000741	CcSEcCtD
Asenapine—Constipation—Epirubicin—uterine cancer	0.000395	0.000735	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.00039	0.000725	CcSEcCtD
Asenapine—Insomnia—Doxorubicin—uterine cancer	0.000387	0.00072	CcSEcCtD
Asenapine—Dyspnoea—Doxorubicin—uterine cancer	0.000381	0.000709	CcSEcCtD
Asenapine—Somnolence—Doxorubicin—uterine cancer	0.00038	0.000707	CcSEcCtD
Asenapine—Dyspepsia—Doxorubicin—uterine cancer	0.000376	0.0007	CcSEcCtD
Asenapine—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000369	0.000687	CcSEcCtD
Asenapine—Fatigue—Doxorubicin—uterine cancer	0.000369	0.000686	CcSEcCtD
Asenapine—Constipation—Doxorubicin—uterine cancer	0.000366	0.00068	CcSEcCtD
Asenapine—Hypersensitivity—Epirubicin—uterine cancer	0.00034	0.000634	CcSEcCtD
Asenapine—Asthenia—Epirubicin—uterine cancer	0.000332	0.000617	CcSEcCtD
Asenapine—Hypersensitivity—Doxorubicin—uterine cancer	0.000315	0.000586	CcSEcCtD
Asenapine—Asthenia—Doxorubicin—uterine cancer	0.000307	0.000571	CcSEcCtD
Asenapine—Dizziness—Epirubicin—uterine cancer	0.000306	0.000569	CcSEcCtD
Asenapine—Vomiting—Epirubicin—uterine cancer	0.000294	0.000547	CcSEcCtD
Asenapine—Rash—Epirubicin—uterine cancer	0.000291	0.000542	CcSEcCtD
Asenapine—Dermatitis—Epirubicin—uterine cancer	0.000291	0.000542	CcSEcCtD
Asenapine—Headache—Epirubicin—uterine cancer	0.00029	0.000539	CcSEcCtD
Asenapine—Dizziness—Doxorubicin—uterine cancer	0.000283	0.000526	CcSEcCtD
Asenapine—Nausea—Epirubicin—uterine cancer	0.000274	0.000511	CcSEcCtD
Asenapine—Vomiting—Doxorubicin—uterine cancer	0.000272	0.000506	CcSEcCtD
Asenapine—Rash—Doxorubicin—uterine cancer	0.00027	0.000502	CcSEcCtD
Asenapine—Dermatitis—Doxorubicin—uterine cancer	0.000269	0.000501	CcSEcCtD
Asenapine—Headache—Doxorubicin—uterine cancer	0.000268	0.000499	CcSEcCtD
Asenapine—Nausea—Doxorubicin—uterine cancer	0.000254	0.000473	CcSEcCtD
Asenapine—ADRB1—GPCR downstream signaling—AKT1—uterine cancer	7.81e-06	0.000165	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—KRAS—uterine cancer	7.81e-06	0.000165	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—KRAS—uterine cancer	7.79e-06	0.000164	CbGpPWpGaD
Asenapine—DRD3—Signaling by GPCR—AKT1—uterine cancer	7.79e-06	0.000164	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—VEGFA—uterine cancer	7.75e-06	0.000164	CbGpPWpGaD
Asenapine—ADRA2B—GPCR downstream signaling—AKT1—uterine cancer	7.74e-06	0.000163	CbGpPWpGaD
Asenapine—ADRA1A—GPCR downstream signaling—PIK3CA—uterine cancer	7.74e-06	0.000163	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—CXCL8—uterine cancer	7.73e-06	0.000163	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	7.73e-06	0.000163	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—CDKN1B—uterine cancer	7.72e-06	0.000163	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—EP300—uterine cancer	7.71e-06	0.000163	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—CXCL8—uterine cancer	7.69e-06	0.000162	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CCL2—uterine cancer	7.69e-06	0.000162	CbGpPWpGaD
Asenapine—HTR1A—Signaling by GPCR—HRAS—uterine cancer	7.68e-06	0.000162	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—EP300—uterine cancer	7.68e-06	0.000162	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—MTHFR—uterine cancer	7.66e-06	0.000162	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—NRAS—uterine cancer	7.65e-06	0.000161	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—KRAS—uterine cancer	7.65e-06	0.000161	CbGpPWpGaD
Asenapine—HTR2C—Signaling by GPCR—HRAS—uterine cancer	7.64e-06	0.000161	CbGpPWpGaD
Asenapine—ADRB2—GPCR downstream signaling—AKT1—uterine cancer	7.64e-06	0.000161	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—EP300—uterine cancer	7.61e-06	0.000161	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—CDKN1B—uterine cancer	7.55e-06	0.000159	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—CDKN1B—uterine cancer	7.51e-06	0.000159	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—CXCL8—uterine cancer	7.48e-06	0.000158	CbGpPWpGaD
Asenapine—HTR1A—GPCR downstream signaling—AKT1—uterine cancer	7.47e-06	0.000158	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—CTNNB1—uterine cancer	7.46e-06	0.000157	CbGpPWpGaD
Asenapine—ADRA2C—Signaling by GPCR—HRAS—uterine cancer	7.44e-06	0.000157	CbGpPWpGaD
Asenapine—HTR2C—GPCR downstream signaling—AKT1—uterine cancer	7.43e-06	0.000157	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—CTNNB1—uterine cancer	7.39e-06	0.000156	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—CDKN1B—uterine cancer	7.31e-06	0.000154	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—VEGFA—uterine cancer	7.31e-06	0.000154	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—CTNNB1—uterine cancer	7.3e-06	0.000154	CbGpPWpGaD
Asenapine—DRD2—Signaling by GPCR—PIK3CA—uterine cancer	7.29e-06	0.000154	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—PTEN—uterine cancer	7.27e-06	0.000153	CbGpPWpGaD
Asenapine—ADRA2C—GPCR downstream signaling—AKT1—uterine cancer	7.23e-06	0.000153	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—NRAS—uterine cancer	7.22e-06	0.000152	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—KRAS—uterine cancer	7.21e-06	0.000152	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—VEGFA—uterine cancer	7.21e-06	0.000152	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—KRAS—uterine cancer	7.21e-06	0.000152	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—PTEN—uterine cancer	7.2e-06	0.000152	CbGpPWpGaD
Asenapine—ADRA2A—GPCR downstream signaling—PIK3CA—uterine cancer	7.19e-06	0.000152	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—PIK3CA—uterine cancer	7.18e-06	0.000151	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—ERBB2—uterine cancer	7.16e-06	0.000151	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—PIK3CA—uterine cancer	7.16e-06	0.000151	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—KRAS—uterine cancer	7.16e-06	0.000151	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—CTNNB1—uterine cancer	7.14e-06	0.000151	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—NRAS—uterine cancer	7.12e-06	0.00015	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—PTEN—uterine cancer	7.11e-06	0.00015	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—KRAS—uterine cancer	7.11e-06	0.00015	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—CTNNB1—uterine cancer	7.1e-06	0.00015	CbGpPWpGaD
Asenapine—ADRB1—Signaling by GPCR—AKT1—uterine cancer	7.09e-06	0.00015	CbGpPWpGaD
Asenapine—HRH2—Signaling Pathways—AKT1—uterine cancer	7.06e-06	0.000149	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—ERBB2—uterine cancer	7.05e-06	0.000149	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—ERBB2—uterine cancer	7.03e-06	0.000148	CbGpPWpGaD
Asenapine—ADRA2B—Signaling by GPCR—AKT1—uterine cancer	7.03e-06	0.000148	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—PIK3CA—uterine cancer	7.03e-06	0.000148	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—KRAS—uterine cancer	7.01e-06	0.000148	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—PTEN—uterine cancer	6.95e-06	0.000147	CbGpPWpGaD
Asenapine—ADRB2—Signaling by GPCR—AKT1—uterine cancer	6.94e-06	0.000146	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—EP300—uterine cancer	6.93e-06	0.000146	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—PTEN—uterine cancer	6.92e-06	0.000146	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—CTNNB1—uterine cancer	6.9e-06	0.000146	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—ERBB2—uterine cancer	6.9e-06	0.000146	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—KRAS—uterine cancer	6.9e-06	0.000146	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—EP300—uterine cancer	6.87e-06	0.000145	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CXCL8—uterine cancer	6.79e-06	0.000143	CbGpPWpGaD
Asenapine—HTR1A—Signaling by GPCR—AKT1—uterine cancer	6.79e-06	0.000143	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—EP300—uterine cancer	6.78e-06	0.000143	CbGpPWpGaD
Asenapine—HTR2C—Signaling by GPCR—AKT1—uterine cancer	6.75e-06	0.000142	CbGpPWpGaD
Asenapine—DRD2—Signaling by GPCR—HRAS—uterine cancer	6.75e-06	0.000142	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—PTEN—uterine cancer	6.73e-06	0.000142	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CXCL8—uterine cancer	6.68e-06	0.000141	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CXCL8—uterine cancer	6.67e-06	0.000141	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—STK11—uterine cancer	6.66e-06	0.000141	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—CYP19A1—uterine cancer	6.66e-06	0.000141	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—HRAS—uterine cancer	6.64e-06	0.00014	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—EP300—uterine cancer	6.63e-06	0.00014	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CDKN1B—uterine cancer	6.63e-06	0.00014	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—PIK3CA—uterine cancer	6.63e-06	0.00014	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—HRAS—uterine cancer	6.62e-06	0.00014	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—PIK3CA—uterine cancer	6.62e-06	0.00014	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—EP300—uterine cancer	6.6e-06	0.000139	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—KRAS—uterine cancer	6.59e-06	0.000139	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—PIK3CA—uterine cancer	6.58e-06	0.000139	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—VEGFA—uterine cancer	6.57e-06	0.000139	CbGpPWpGaD
Asenapine—ADRA2C—Signaling by GPCR—AKT1—uterine cancer	6.57e-06	0.000139	CbGpPWpGaD
Asenapine—DRD2—GPCR downstream signaling—AKT1—uterine cancer	6.56e-06	0.000138	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CXCL8—uterine cancer	6.54e-06	0.000138	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—PTEN—uterine cancer	6.54e-06	0.000138	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—PIK3CA—uterine cancer	6.53e-06	0.000138	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CDKN1B—uterine cancer	6.53e-06	0.000138	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CDKN1B—uterine cancer	6.51e-06	0.000137	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—VEGFA—uterine cancer	6.51e-06	0.000137	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—HRAS—uterine cancer	6.5e-06	0.000137	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—NRAS—uterine cancer	6.49e-06	0.000137	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—MTHFR—uterine cancer	6.49e-06	0.000137	CbGpPWpGaD
Asenapine—HTR2A—GPCR downstream signaling—AKT1—uterine cancer	6.45e-06	0.000136	CbGpPWpGaD
Asenapine—HRH1—GPCR downstream signaling—AKT1—uterine cancer	6.44e-06	0.000136	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—PIK3CA—uterine cancer	6.44e-06	0.000136	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—NRAS—uterine cancer	6.43e-06	0.000136	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—VEGFA—uterine cancer	6.42e-06	0.000136	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—EP300—uterine cancer	6.42e-06	0.000135	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—TP53—uterine cancer	6.41e-06	0.000135	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—ERBB2—uterine cancer	6.41e-06	0.000135	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—TP53—uterine cancer	6.41e-06	0.000135	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CDKN1B—uterine cancer	6.39e-06	0.000135	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—TP53—uterine cancer	6.36e-06	0.000134	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—NRAS—uterine cancer	6.35e-06	0.000134	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—PIK3CA—uterine cancer	6.34e-06	0.000134	CbGpPWpGaD
Asenapine—ADRA1A—GPCR downstream signaling—AKT1—uterine cancer	6.32e-06	0.000133	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—VEGFA—uterine cancer	6.28e-06	0.000133	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CTNNB1—uterine cancer	6.27e-06	0.000132	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—VEGFA—uterine cancer	6.25e-06	0.000132	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—EP300—uterine cancer	6.23e-06	0.000132	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—TP53—uterine cancer	6.23e-06	0.000132	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—KRAS—uterine cancer	6.21e-06	0.000131	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—NRAS—uterine cancer	6.2e-06	0.000131	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—NRAS—uterine cancer	6.17e-06	0.00013	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CTNNB1—uterine cancer	6.16e-06	0.00013	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CTNNB1—uterine cancer	6.15e-06	0.00013	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—HRAS—uterine cancer	6.13e-06	0.000129	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—TP53—uterine cancer	6.13e-06	0.000129	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—KRAS—uterine cancer	6.13e-06	0.000129	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—HRAS—uterine cancer	6.13e-06	0.000129	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—PTEN—uterine cancer	6.11e-06	0.000129	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—HRAS—uterine cancer	6.09e-06	0.000128	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CXCL8—uterine cancer	6.08e-06	0.000128	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—VEGFA—uterine cancer	6.08e-06	0.000128	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—PIK3CA—uterine cancer	6.05e-06	0.000128	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—HRAS—uterine cancer	6.04e-06	0.000127	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CTNNB1—uterine cancer	6.04e-06	0.000127	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—PTEN—uterine cancer	6.01e-06	0.000127	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—NRAS—uterine cancer	6e-06	0.000127	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—PTEN—uterine cancer	6e-06	0.000127	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—HRAS—uterine cancer	5.96e-06	0.000126	CbGpPWpGaD
Asenapine—DRD2—Signaling by GPCR—AKT1—uterine cancer	5.96e-06	0.000126	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CDKN1B—uterine cancer	5.94e-06	0.000125	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—PTEN—uterine cancer	5.88e-06	0.000124	CbGpPWpGaD
Asenapine—ADRA2A—GPCR downstream signaling—AKT1—uterine cancer	5.87e-06	0.000124	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—HRAS—uterine cancer	5.86e-06	0.000124	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—AKT1—uterine cancer	5.86e-06	0.000124	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—TP53—uterine cancer	5.85e-06	0.000124	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—AKT1—uterine cancer	5.85e-06	0.000123	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—EP300—uterine cancer	5.82e-06	0.000123	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—AKT1—uterine cancer	5.74e-06	0.000121	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—EP300—uterine cancer	5.73e-06	0.000121	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—EP300—uterine cancer	5.72e-06	0.000121	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.72e-06	0.000121	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—PIK3CA—uterine cancer	5.71e-06	0.00012	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—PIK3CA—uterine cancer	5.68e-06	0.00012	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—PIK3CA—uterine cancer	5.63e-06	0.000119	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—EP300—uterine cancer	5.61e-06	0.000118	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CTNNB1—uterine cancer	5.61e-06	0.000118	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—HRAS—uterine cancer	5.6e-06	0.000118	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—KRAS—uterine cancer	5.58e-06	0.000118	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—KRAS—uterine cancer	5.53e-06	0.000117	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—TP53—uterine cancer	5.52e-06	0.000117	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—VEGFA—uterine cancer	5.52e-06	0.000116	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—PTEN—uterine cancer	5.47e-06	0.000115	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—KRAS—uterine cancer	5.46e-06	0.000115	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—NRAS—uterine cancer	5.45e-06	0.000115	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—TP53—uterine cancer	5.45e-06	0.000115	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—VEGFA—uterine cancer	5.43e-06	0.000115	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—VEGFA—uterine cancer	5.42e-06	0.000114	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—AKT1—uterine cancer	5.41e-06	0.000114	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—AKT1—uterine cancer	5.41e-06	0.000114	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—AKT1—uterine cancer	5.37e-06	0.000113	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—NRAS—uterine cancer	5.36e-06	0.000113	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—NRAS—uterine cancer	5.35e-06	0.000113	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—KRAS—uterine cancer	5.34e-06	0.000113	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—AKT1—uterine cancer	5.33e-06	0.000113	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—VEGFA—uterine cancer	5.31e-06	0.000112	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—KRAS—uterine cancer	5.31e-06	0.000112	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—HRAS—uterine cancer	5.28e-06	0.000111	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—AKT1—uterine cancer	5.26e-06	0.000111	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—NRAS—uterine cancer	5.25e-06	0.000111	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—EP300—uterine cancer	5.21e-06	0.00011	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—HRAS—uterine cancer	5.21e-06	0.00011	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—AKT1—uterine cancer	5.18e-06	0.000109	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—KRAS—uterine cancer	5.17e-06	0.000109	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—PIK3CA—uterine cancer	5.13e-06	0.000108	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—PIK3CA—uterine cancer	5.08e-06	0.000107	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—PIK3CA—uterine cancer	5.02e-06	0.000106	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—MTHFR—uterine cancer	5.01e-06	0.000106	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—TP53—uterine cancer	4.96e-06	0.000105	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—AKT1—uterine cancer	4.94e-06	0.000104	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—VEGFA—uterine cancer	4.94e-06	0.000104	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—TP53—uterine cancer	4.92e-06	0.000104	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—PIK3CA—uterine cancer	4.91e-06	0.000104	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—PIK3CA—uterine cancer	4.88e-06	0.000103	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—NRAS—uterine cancer	4.88e-06	0.000103	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—TP53—uterine cancer	4.85e-06	0.000102	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—PIK3CA—uterine cancer	4.75e-06	0.0001	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—TP53—uterine cancer	4.75e-06	0.0001	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—HRAS—uterine cancer	4.75e-06	0.0001	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—TP53—uterine cancer	4.72e-06	9.97e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—HRAS—uterine cancer	4.7e-06	9.93e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—KRAS—uterine cancer	4.69e-06	9.9e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—AKT1—uterine cancer	4.66e-06	9.84e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—HRAS—uterine cancer	4.64e-06	9.8e-05	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—AKT1—uterine cancer	4.64e-06	9.79e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—KRAS—uterine cancer	4.61e-06	9.74e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—PIK3CA—uterine cancer	4.61e-06	9.73e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—KRAS—uterine cancer	4.6e-06	9.72e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—AKT1—uterine cancer	4.6e-06	9.71e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—TP53—uterine cancer	4.59e-06	9.69e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—HRAS—uterine cancer	4.54e-06	9.58e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—KRAS—uterine cancer	4.52e-06	9.54e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—HRAS—uterine cancer	4.52e-06	9.53e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—HRAS—uterine cancer	4.39e-06	9.27e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—PIK3CA—uterine cancer	4.31e-06	9.09e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PTEN—uterine cancer	4.26e-06	8.99e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—PIK3CA—uterine cancer	4.24e-06	8.95e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—PIK3CA—uterine cancer	4.23e-06	8.93e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—KRAS—uterine cancer	4.2e-06	8.86e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—AKT1—uterine cancer	4.19e-06	8.84e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—TP53—uterine cancer	4.17e-06	8.8e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—AKT1—uterine cancer	4.15e-06	8.76e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—PIK3CA—uterine cancer	4.15e-06	8.76e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—TP53—uterine cancer	4.1e-06	8.66e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—AKT1—uterine cancer	4.1e-06	8.65e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—TP53—uterine cancer	4.09e-06	8.64e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—EP300—uterine cancer	4.06e-06	8.57e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—TP53—uterine cancer	4.02e-06	8.47e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—AKT1—uterine cancer	4.01e-06	8.46e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—AKT1—uterine cancer	3.99e-06	8.42e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—HRAS—uterine cancer	3.99e-06	8.41e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—HRAS—uterine cancer	3.92e-06	8.28e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—HRAS—uterine cancer	3.91e-06	8.26e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—AKT1—uterine cancer	3.88e-06	8.19e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—PIK3CA—uterine cancer	3.86e-06	8.14e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—HRAS—uterine cancer	3.84e-06	8.1e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—AKT1—uterine cancer	3.77e-06	7.95e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—TP53—uterine cancer	3.73e-06	7.87e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PTEN—uterine cancer	3.61e-06	7.62e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—HRAS—uterine cancer	3.57e-06	7.53e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—AKT1—uterine cancer	3.52e-06	7.43e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—AKT1—uterine cancer	3.46e-06	7.31e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—AKT1—uterine cancer	3.46e-06	7.29e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—EP300—uterine cancer	3.44e-06	7.26e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—AKT1—uterine cancer	3.39e-06	7.16e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—AKT1—uterine cancer	3.15e-06	6.65e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PIK3CA—uterine cancer	3.01e-06	6.34e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PTEN—uterine cancer	2.79e-06	5.88e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—EP300—uterine cancer	2.66e-06	5.61e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CA—uterine cancer	2.55e-06	5.37e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—AKT1—uterine cancer	2.45e-06	5.18e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—AKT1—uterine cancer	2.08e-06	4.39e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.96e-06	4.15e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—AKT1—uterine cancer	1.61e-06	3.39e-05	CbGpPWpGaD
